Revolutionary Cancer Therapy: Sona Nanotech's Gold Nanorods Shrink Tumors from the Inside Out

Sona Nanotech (CSE:SONA,OTCQB:SNANF) is ramping up clinical trials for its targeted hyperthermia therapy (THT) for cancer. CEO David Regan said the company is looking forward to taking THT into in-human studies after interim results from its efficacy study on animals showed statistically significantly superior results.

00:00 Introduction
00:46 Breakthrough in cancer treatment with Sona's targeted hyperthermia therapy (THT)
01:53 Advancing cancer therapy through preclinical trials and collaboration
04:20 Innovative cancer therapy using gold nanorods and infrared light
05:29 Targeting tumors with heat and immunotherapy
06:24 How hyperthermia therapy is used in clinical studies
08:01 Efficacy of hyperthermia therapy in combination with other immunotherapy drugs
09:26 Promising early results in groundbreaking medical studies




#cancertreatment #lifesciencestocks #investing
________________________________________________________________


Investing News Network (INN)

Find out more about Sona Nanotech: https://bit.ly/3V6XJ94

Browse our 2023 outlook reports:
http://bit.ly/3JHyR1M

Follow us Facebook:
  / investing.news.your.trusted.source  

Follow us on Twitter:
@INN_Resource

________________________________________________________________


The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.